SPDYA

speedy/RINGO cell cycle regulator family member A, the group of Speedy/RINGO cell cycle regulator family

Basic information

Region (hg38): 2:28782517-28850611

Previous symbols: [ "SPDY1" ]

Links

ENSG00000163806NCBI:245711OMIM:614029HGNC:30613Uniprot:Q5MJ70AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SPDYA gene.

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SPDYA gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
0
missense
9
clinvar
1
clinvar
1
clinvar
11
nonsense
0
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
0
non coding
4
clinvar
4
Total 0 0 13 1 1

Variants in SPDYA

This is a list of pathogenic ClinVar variants found in the SPDYA region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
2-28783650-G-A Benign (Oct 16, 2018)1221779
2-28783714-G-A Likely benign (Jun 06, 2019)1207460
2-28783725-G-C Benign (Oct 01, 2018)1289295
2-28783757-G-GA Benign (Aug 12, 2019)1221102
2-28783890-C-T Likely benign (Apr 07, 2023)1657293
2-28783893-C-G Likely benign (Mar 07, 2023)2972866
2-28783893-C-T Likely benign (Mar 26, 2023)2846001
2-28783895-T-G Likely benign (Apr 28, 2022)1603222
2-28783899-A-G Likely benign (Jul 17, 2021)1572505
2-28783900-T-C Likely benign (Mar 29, 2023)2969607
2-28783902-T-G Likely benign (Jul 29, 2022)1633115
2-28783909-T-C Likely benign (Jul 29, 2023)1950707
2-28783923-G-A Likely benign (Apr 08, 2022)1648376
2-28783923-G-T Cardiovascular phenotype Likely benign (Aug 31, 2021)1747164
2-28783925-A-C Uncertain significance (Sep 10, 2023)2796814
2-28783930-A-G Noonan syndrome Uncertain significance (Feb 03, 2023)981575
2-28783931-T-A Noonan syndrome • Noonan syndrome-like disorder with loose anagen hair 2 Conflicting classifications of pathogenicity (Jan 07, 2022)974912
2-28783934-A-C Noonan syndrome-like disorder with loose anagen hair 2 • Cardiovascular phenotype Pathogenic (Dec 11, 2023)254652
2-28783934-A-T Noonan syndrome-like disorder with loose anagen hair 2 Pathogenic (Sep 08, 2016)254651
2-28783948-A-G Uncertain significance (Aug 07, 2022)1715452
2-28783979-G-GT Uncertain significance (Mar 19, 2023)2793832
2-28783992-G-C Likely benign (Sep 26, 2023)1533211
2-28783996-TTTAA-T Likely benign (Oct 13, 2023)1537362
2-28784096-C-T Likely benign (Oct 24, 2018)1211536
2-28784117-C-T Likely benign (Mar 17, 2019)1207392

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
SPDYAprotein_codingprotein_codingENST00000334056 668095
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.5510.4481257050231257280.0000915
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.561051610.6530.000007982063
Missense in Polyphen2655.4030.46929708
Synonymous0.5684752.20.9000.00000246548
Loss of Function2.92315.30.1967.29e-7212

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0002240.000223
Ashkenazi Jewish0.000.00
East Asian0.0001140.000109
Finnish0.00009270.0000924
European (Non-Finnish)0.00007210.0000703
Middle Eastern0.0001140.000109
South Asian0.0002010.000196
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Regulates the G1/S phase transition of the cell cycle by binding and activating CDK1 and CDK2 (PubMed:12972555). Contributes to CDK2 activation without promoting CDK2 phosphorylation, by inducing a conformation change of the CDK2 T- loop that obstructs the substrate-binding cleft prior to kinase activation (PubMed:28666995). Mediates cell survival during the DNA damage process through activation of CDK2 (PubMed:12839962). {ECO:0000269|PubMed:11980914, ECO:0000269|PubMed:12839962, ECO:0000269|PubMed:12972555, ECO:0000269|PubMed:28666995}.;
Pathway
Oocyte meiosis - Homo sapiens (human);Progesterone-mediated oocyte maturation - Homo sapiens (human) (Consensus)

Recessive Scores

pRec
0.0839

Intolerance Scores

loftool
0.347
rvis_EVS
0.1
rvis_percentile_EVS
61.28

Haploinsufficiency Scores

pHI
0.0611
hipred
Y
hipred_score
0.730
ghis

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.812

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Spdya
Phenotype
homeostasis/metabolism phenotype; cellular phenotype; endocrine/exocrine gland phenotype; reproductive system phenotype;

Gene ontology

Biological process
G1/S transition of mitotic cell cycle;cellular response to DNA damage stimulus;male meiotic nuclear division;multicellular organism development;positive regulation of cell population proliferation;activation of protein kinase activity;positive regulation of cyclin-dependent protein serine/threonine kinase activity;positive regulation of protein kinase activity
Cellular component
nucleus;nucleoplasm
Molecular function
protein kinase binding;protein kinase activator activity